Quantinno Capital Management LP Has $16.86 Million Stock Position in Becton, Dickinson and Company $BDX

Quantinno Capital Management LP lessened its holdings in Becton, Dickinson and Company (NYSE:BDX) by 8.2% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 107,198 shares of the medical instruments supplier’s stock after selling 9,554 shares during the quarter. Quantinno Capital Management LP’s holdings in Becton, Dickinson and Company were worth $16,855,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of BDX. Auto Owners Insurance Co raised its stake in Becton, Dickinson and Company by 22,225.2% in the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock worth $790,079,000 after purchasing an additional 40,528,680 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Becton, Dickinson and Company by 9,056.3% in the third quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock valued at $979,290,000 after buying an additional 5,174,944 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Becton, Dickinson and Company by 13.0% in the fourth quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock valued at $7,118,282,000 after buying an additional 4,223,149 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Becton, Dickinson and Company by 23,219.2% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier’s stock valued at $769,397,000 after buying an additional 4,137,888 shares during the period. Finally, Norges Bank acquired a new stake in Becton, Dickinson and Company during the fourth quarter worth approximately $734,321,000. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $166.19 on Monday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The stock has a market capitalization of $45.79 billion, a P/E ratio of 42.07, a price-to-earnings-growth ratio of 11.80 and a beta of 0.19. The stock has a fifty day moving average of $151.85 and a 200-day moving average of $163.37.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. During the same period last year, the firm posted $3.35 earnings per share. Becton, Dickinson and Company’s revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, sell-side analysts expect that Becton, Dickinson and Company will post 12.53 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.5%. Becton, Dickinson and Company’s payout ratio is 106.33%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the sale, the executive vice president owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at $16,122,355.05. This trade represents a 2.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 5,189 shares of company stock valued at $765,661. 0.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Wells Fargo & Company raised their price objective on Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. Stifel Nicolaus reduced their target price on Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. UBS Group began coverage on Becton, Dickinson and Company in a research report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price target on the stock. The Goldman Sachs Group dropped their price target on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research note on Wednesday, May 27th. Finally, Barclays upped their price objective on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average target price of $180.93.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.